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Abstract 
While Aβ peptides derived from amyloid precursor protein (APP) play a key role in Alzheimer 
disease pathogenesis, the extracellular sAPPα soluble ectodomain has been shown to stimulate 
adult neurogenesis and synaptic plasticity. Elevated expression of App in the choroid plexus 
has been recently reported, suggesting an important role for APP in cerebrospinal fluid. We 
conditionally knocked down App expression specifically in the adult mouse choroid plexus 
either by genetic deletion or shRNA expression, which led to reduced proliferation in both 
subventricular zone and hippocampus dentate gyrus neurogenic niches. Conversely, 
proliferation in both niches was increased either by viral expression of App in choroid plexus 
or by infusion of sAPPα but not sAPPβ in cerebrospinal fluid. To test the hypothesis that 
favoring the production of Aβ specifically in choroid plexus could negatively affect niche 
functions, we used AAV5 mediated expression of human mutated APP specifically in the 
choroid plexus of adult wild type mice. These mice showed reduced niche proliferation and, 
after one year, exhibited behavioral defects in reversal learning. Consistent with impaired 
memory, electrophysiological analysis revealed impaired synaptic plasticity as evidenced by 
deficits in hippocampal LTP. Our findings highlight the unique role played by the choroid 
plexus in regulating brain function, and suggest that targeting APP in choroid plexus may 
provide a means to improve hippocampus function and alleviate disease-related burdens.  
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Introduction 
Alzheimer disease (AD) is a neurodegenerative disease that affects the aging human population. 
Genetic risk factors include AD associated mutations in the amyloid precursor protein (APP) 
and presenilin 1 (PSEN1 and PSEN2) genes and others (e.g. APOE4 allele) contributing to the 
onset and development of the disease [16]. Pathologically, the brain of AD patients is 
characterized by neurofibrillary tangles, consisting of hyperphosphorylated forms of the 
microtubule-associated protein TAU, and by amyloid plaque deposits, enriched in extracellular 
and intracellular Aβ40 and Aβ42 (thereafter Aβ) amyloid peptides. Aβ peptides are generated 
from APP by sequential proteolytic cleavage by β- and !-secretases, while cleavage by α-
secretase releases the secreted APPα ectodomain (sAPPα) from the cell surface. Due to the 
position of the 3 cleavage sites, the secretion of sAPPα precludes the generation of Aβ peptides. 
In contrast, cleavage at the β site releases the sAPPβ ectodomain, in parallel with Aβ peptide 
production.  
An important and still under-investigated issue is the physiological function of sAPPα. Indeed, 
the pathological traits accompanying amyloid plaque formation could potentially be explained 
by a parallel decrease of sAPPα levels resulting in lost functions that cannot be compensated 
by sAPPβ [33]. Key functions of sAPPα include its ability to enhance spine density, synaptic 
plasticity and memory, as well as neurogenesis [24, 28]. Expression of sAPP⍺ in hippocampus 
has been shown to rescue cognition and synaptic transmission and to mitigate synaptic and 
cognitive deficits in a pathological context [12, 43, 50]. sAPP⍺ dependent signals are important 
for neuroprotection through sAPPα binding to transmembrane APP [23], and in synaptic 
plasticity through binding to partners such as the recently identified GABABR1a ligand and the ⍺7-nACh receptor [26, 32, 33]. Furthermore, APP plays a role in neurogenesis, either as full-
length transmembrane APP [47] or through its sAPPα ectodomain [4]. In the latter study, it was 
shown that sAPPα acts through binding to the EGF receptor, but the cellular source of the 
sAPPα ectodomain was not identified.   
In addition to neurofibrillary tangles and amyloid plaques, a deficit in adult neurogenesis has 
been associated with AD [5, 25, 34, 45, 49]. Although adult neurogenesis in humans has been 
recently challenged [30, 44], it has been demonstrated conclusively in rodents, with two 
primary neurogenic sites, the subventricular zone (SVZ) and the subgranular zone (SGZ) of the 
hippocampal dentate gyrus (DG). Neuroblasts produced in the rodent SVZ migrate away into 
the olfactory bulb where they differentiate into inhibitory neurons. In the hippocampus, 
neuroblasts integrate locally in DG and differentiate into glutamatergic neurons. Humans 
constitute an important exception since SVZ-derived neuroblasts may migrate into the striatum 
[10]. In the transgenic APP/PS1 mouse model of AD, a decrease in adult SGZ neurogenesis 
was observed in addition to amyloid plaques throughout the brain parenchyma including the 
hippocampus [51]. Moreover, sAPPα stimulates the proliferation of SVZ and SGZ neural 
progenitors [1, 4, 8], while viral expression of sAPPα in the hippocampus of the APP/PS1 
mouse rescues synaptic failure [12]. Although circumstantial, these results evoke the possibility 
that an impairment in adult neurogenesis may contribute to healthy and pathological ageing. In 
fact, even if the recent controversy on adult neurogenesis in the humans cannot be ignored, a 
recent study convincingly showed that adult DG neurogenesis is maintained at a high level until 
old age but drops sharply in AD patients, supporting the AD “neurogenesis” hypothesis of 
cognitive impairment [25].  
The cerebrospinal fluid (CSF) has been recognized recently as an important contributor to the 
neurogenic niche [3, 19, 38]. Trophic factors, transcription factors and guidance molecules are 
secreted by the choroid plexus (ChPl) into the CSF. We previously showed that sAPPa infused 
in the CSF recognizes stem cells expressing the EGF-receptor within the SVZ and enhances 
their proliferation, while no effect on hippocampal neurogenesis was observed [4]. In line with 
these observations, we aimed to evaluate the importance of the ChPl in regulating adult 
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neurogenesis and to explore the possibility that the ChPl might constitute an important actor 
and translational target in healthy and pathological aging. We report that sAPPa produced 
specifically from the ChPl positively affects proliferation in both neurogenic niches. 
Conversely, we used serotype 5 adeno-associated virus (AAV5) vectors specifically targeting 
the ChPl to express human APP bearing the Swedish-Indiana (SwInd) mutations, thus favoring 
Aβ production, which resulted in reduced proliferation in both niches, caused defects in reversal 
learning and impaired synaptic plasticity mechanisms in the hippocampus.  
 
 
Materials and Methods 
Animals and ethics 
C57Bl/6J mice were purchased from Janvier (France) and Appflox/flox mice were described 
previously [22]. All colonies were maintained under a 12:12 light/dark cycle with free access 
to food and water. In environmental enrichment experiments, Appflox/flox mice were placed in 
cages with running wheels (2 mice per cage) 7 days before surgery and kept for 15 days in these 
cages before analysis. All animal procedures were carried out in accordance with the guidelines 
of the European Economic Community (2010/63/UE) and the French National Committee 
(2013/118). For surgical procedures, animals were anesthetized with xylazine (Rompun 2%, 5 
mg/kg) and ketamine (Imalgene 1000, 80 mg/kg) by intraperitoneal injection. This project (no. 
00702.01) obtained approval from Ethics committee no. 59 of the French Ministry for Research 
and Higher Education.  
 
Protein and virus stereotaxic surgery 
Vectored Cre recombinase protein, Cre-Tat, was produced as previously described [41]. Adeno-
associated virus (AAV) were of serotype 5 and purchased from either SignaGen [AAV5-CMV-
eGFP-U6-shRNA(mAβ42) and AAV5-CMV-eGFP-U6-shRNA(scrambled mAβ42)] or Vector 
Biolabs [AAV5-CMV-eGFP-2A-mAPP[NM_007471.3], AAV5-CMV-mCherry-2A-
hAPP(SwInd), and AAV5-CMV-eGFP]. The hAPP(SwInd) sequence is a form of human APP 
[NM_201414.2] bearing both Swedish (K670N/M671L) and Indiana (V717F) related 
mutations. Cre-Tat protein (~30 µg), vehicle (protein vehicle is 1.8% NaCl, 15% DMSO; virus 
vehicle is 0.9% NaCl), or high-titer AAVs (~1013 GC/ml) were injected (2 µl per mouse) into 
the right lateral ventricle (coordinates from bregma: x, -0.58 mm; y, +1.28 mm; z, -2 mm) with 
a 10 µl Hamilton syringe (0.2 µl/min). For protein infusion (3.5 µg per mouse), sAPPα (Sigma-
Aldrich), sAPPβ (Sigma-Aldrich), or vehicle were infused for either 7 or 15 days with 100 µl 
osmotic mini pumps (Alzet) implanted at the same stereotaxic coordinates as above. 
 
Reversal learning 
Spatial memory was assessed by the Morris water maze test [6] in which mice use visual cues 
to locate an escape platform (9 cm in diameter) in an open circular swimming arena (150 cm in 
diameter, 40 cm deep) filled with opaque water (Acusol, 20 ± 1 °C). The escape platform was 
hidden 1 cm below the water surface. Room temperature was kept constant at 24°C and both 
arena placement and surrounding visual cues were kept fixed during all experiments. Data was 
acquired by the SMART recording system and tracking software (Panlab). Data processing was 
automated with NAT (Navigation Analysis Tool), an in-house tool rooted in MATLAB [18]. 
Mice underwent a two-phase training protocol (Fig. 4e). The first phase consisted of 5 training 
days, 1 day of rest followed by probe test 1 (initial learning). For the second phase, the platform 
was moved to a different quadrant, and again training lasted 5 days followed by 1 day of rest 
before probe test 2 (reversal learning). Training sessions consisted of 4 daily swimming trials 
(1 h interval between trials) starting randomly from different positions, with each quadrant 
sampled once per day. For each trial, mice were released at a starting point facing the inner wall 
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and given a maximum of 90 s to locate and climb onto the escape platform. Mice that failed to 
locate the platform within 90 s were guided to it. In either case, mice were allowed to stay on 
the platform for 30 s. To assess spatial memory, probe tests were performed 24 h after the last 
training session by tracking mice for 60 s with the platform absent. Measured parameters during 
the training phases were the average time taken to reach the platform (i.e., mean escape latency) 
and the average speed.  Measured parameters during probe tests were the mean distance traveled 
by the mouse before arriving at the platform location, % time spent in the target quadrant, and 
the number of platform location crossings. 
 
Electrophysiology 
Acute transverse hippocampal slices (400 µm) were prepared as previously described [29]. 
Briefly, mice were culled by cervical dislocation and decapitation. Brains were rapidly removed 
and placed in chilled (1-4 °C) artificial cerebrospinal fluid (aCSF) composed of (in mM) 119 
NaCl, 2.5 KCl, 0.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 26.2 NaHCO3 and 11 glucose. After 
sectioning, hippocampal slices were maintained at room temperature in a storage chamber 
containing aCSF saturated with 95% O2 and 5% CO2 for at least 1 h before the experiments. 
Slices were then transferred to a submerged recording chamber mounted on a Scientifica 
SliceScope Pro 6000 microscope equipped for infrared-differential interference (IR-DIC) 
microscopy and were perfused with aCSF (2 ml/min) at RT. All experiments were performed 
in CA1 stratum radiatum region of the hippocampus. Field excitatory postsynaptic potentials 
(fEPSPs) were recorded with glass pipettes (2–5 MΩ) filled with 1 M NaCl. Postsynaptic 
responses were evoked by stimulating Schaffer collaterals (0.033 Hz) in CA1 stratum radiatum 
with aCSF-filled glass pipettes. Input/output relationships of evoked excitatory postsynaptic 
potentials (EPSPs) were assayed by incrementing stimulation strength (5 to 50 µA, 100 µs). 
The test-shock used in subsequent experiments was chosen to elicit 50% of the maximal slope. 
Paired-pulse experiments consisted of 2 identical stimuli with increasing inter-pulse intervals 
(50 to 250 ms). Paired-pulse ratios were generated by plotting the maximum slope of the second 
fEPSP as a percentage of the first. Long-term potentiation (LTP) was induced by high-
frequency stimulation (HFS: 2 trains of 100 pulses at 100 Hz, 30 s inter-train interval). 
 
PCR and Western blots 
Mice were anesthetized for intracardiac perfusion with PBS. Subsequently, choroid plexus, 
hippocampus, cortex, retina and/or SVZ samples were extracted in ice-cold PBS, frozen on dry 
ice, and stored at -20 °C. Genomic DNA, total RNA and proteins were recovered by using the 
Allprep DNA/RNA/Protein Mini Kit (Qiagen 80004). The efficiency of Cre-induced 
recombination in Appflox/flox mice was verified by PCR with primers F, C and D previously 
described [22]. For quantitative RT-PCR, cDNA was synthetized from 13 ng total RNA with 
QuantiTect Reverse Transciption Kit (Qiagen 205313). Quantitative PCR reactions were 
carried out in triplicate with SYBR Green I Master Mix (Roche S-7563) on a LightCycler 480 
system (Roche). Expression was calculated by using the 2−ΔΔCt method with Gapdh as a 
reference. For Western blot analysis, proteins samples were separated on NuPAGE 4-12% Bis-
Tris pre-cast gels (Invitrogen NP0321) at 200 V for 1 h and transferred onto a methanol-
activated PVDF membrane at 400 mV for 1 h. Primary antibody anti-APP (22C11 mouse 1:500, 
Millipore MAB348) was incubated overnight at 4 °C and anti-mouse-HRP-coupled secondary 
antibody (1:3000, Life Technologies) was incubated for 1.5 h at RT. Signal was detected by 
SuperSignal West Femto Substrate (Thermo Scientific 34095) with a LAS-4000 gel imager 
(Fujifilm) and quantified by densitometry with ImageJ. 
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Histology 
Mice were anesthetized for intracardiac perfusion with PBS, and brains were subsequently 
removed and fixed in 4% paraformaldehyde for 3 days. Coronal sections (60 µm) were obtained 
by Vibratome (Microm). For immunostaining, floating sections were steamed 10 min in citrate 
buffer (10 mM sodium citrate pH 6.0, 0.05% Tween), washed in PBS and treated with blocking 
solution (PBS pH 7, 1% triton-X100, 5% normal goat serum) for 1 h. Primary antibody anti-
Ki67 (SP6 rabbit 1:500, Abcam ab16667) was incubated overnight at 4 °C in blocking solution 
and biotinylated anti-rabbit IgG secondary antibody (1:3000, Vector Laboratories BA-1000) at 
RT for 1h. Staining was visualized by using the Vectastain ABC HRP kit (Vector Laboratories 
PK-6100) with the DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories SK-4100). Ki67-
positive cells were counted manually in the DG on 5 sections per mouse (sections 180 µm apart, 
n = 5 to 8 mice per group). Cells in SVZ were counted by StereoInvestigator (Stereology 
Software, MBF Bioscience) on 8 sections per mouse (sections 180 µm apart, n = 5 to 8 mice 
per group). 
 
Statistical Analysis 
Morris water maze training data (escape latency and speed) were analyzed with two-way 
repeated measures ANOVA with Statview 5.0.1 (SAS). Probe test data were analyzed for 
normality (D'Agostino & Pearson omnibus normality test) and unpaired t test was used for 
group comparisons with Statview 5.0.1 (SAS). Electrophysiological data were analyzed by 
ANOVA with Statistica 6.1 and Statview 5.0.1. Histological and biochemical data were 
analyzed by unpaired t test or ANOVA (as described in Figure legends) with Prism v6 
(GraphPad). All data are given as mean ± standard error of the mean (SEM).  
 
 
Results 
App is highly expressed in the adult choroid plexus 
Given that ventricular infusion of recombinant sAPPα has been shown to affect SVZ 
proliferation [4, 8], and that the ChPl has been shown to express APP [21], we hypothesized 
that the ChPl is a potential endogenous source for CSF-borne sAPPα. Indeed, App is one of the 
most highly expressed ChPl genes [2]. We confirmed high App expression levels in the ChPl 
by qPCR. In comparison to the hippocampus (that has been shown previously to strongly 
express APP) and the SVZ, we found higher and elevated levels in ChPl in lateral and 4th 
ventricles of 4-month-old adult mice (Fig. 1a). Interestingly, Transthyretin and Apoe, two genes 
involved in App functions [7, 40] are also very highly expressed in the ChPl [2, 39]. 
 
App knock-down in the choroid plexus decreases adult proliferation  
In order to knock down App expression locally and specifically in ChPl, we performed Cre-Tat 
intracerebroventricular (icv) injections in 10-month-old Appflox/flox mice (Fig. 1b). Cre-mediated 
deletion of the App locus and App expression were evaluated 15 days later in various structures 
including retina, hippocampus, cortex and ChPl (Fig. 1b-f). The specificity of Cre-Tat targeting 
selectively the ChPl was confirmed by the absence of recombination in other structures (Fig. 
1c), as previously demonstrated for another floxed mouse model [41]. Consequently, only in 
ChPl do we observe a decrease in App mRNA (by 37 ± 7%, Fig. 1d) and APP protein (by 52 ± 
3%, Fig. 1e-f).  
To evaluate the impact of App knock-down on cell proliferation, ~3-month-old Appflox/flox mice 
were injected with vehicle or Cre-Tat and subsequently implanted with 15-day osmotic 
minipumps for CSF infusion of either vehicle or sAPPα (Fig. 1g). Compared to vehicle 
injected/infused controls, animals injected with Cre-Tat and infused with vehicle showed a 
significant reduction in the number of proliferating cells in the SVZ (Fig. 1h). This decrease 
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was rescued by infusion of sAPPα (Fig. 1h), suggesting that knock-down of sAPPα leads to 
impaired neurogenesis. In contrast, this experimental paradigm did not alter DG proliferation 
(Fig. 1i-j), even under enriched environment conditions with free access to running wheels 
known to stimulate hippocampal proliferation [46].  
In order to reduce App levels more robustly in the ChPl, a viral vector expressing shRNA 
against the mouse βA42 sequence was injected into the ventricles of ~3-month-old wild type 
mice (Fig. 2a). As previously reported [48], icv injection of AAV5 results in specific ChPl 
targeting, and indeed we did not detect expression of co-expressed eGFP marker protein in the 
parenchyma (Fig. 2b). Eight weeks post-injection, App (mRNA) and APP protein decreased 
nearly 5-fold in ChPl with no change in hippocampus and cortex levels (Fig. 2c-e). This 
decrease led to a significant reduction in the number of proliferating cells in both SVZ and DG 
(Fig. 2f-i). 
 
sAPPα gain-of-function in either cerebrospinal fluid or choroid plexus increases adult 
proliferation  
To further investigate the impact of sAPP on adult neurogenesis, either sAPPα or sAPPβ was 
infused for 7 days in the lateral ventricles of ~3-month-old wild type mice (Fig. 3a). APP can 
be cleaved either along the non-amyloidogenic pathway to give rise to sAPPα or along the 
amyloidogenic pathway to produce its sAPPβ counterpart, and the icv injection of the two sAPP 
forms has been previously shown to have opposite effects on neurogenesis [8]. In our paradigm, 
infusion of sAPPα but not of sAPPβ increased the number of proliferating cells both in the SVZ 
and DG of adult mice (Fig. 3b-e). To confirm that CSF and choroid plexus sAPPα gain-of-
function are correlated, icv injections of AAV5 expressing mouse App were performed for 
ChPl-specific over-expression (Fig. 3f). After 8 weeks, the relative App expression was 
increased by approximately 2-fold (Fig. 3g), resulting in a significant increase in the number of 
proliferating cells in both the SVZ and DG (Fig. 3h-i). 
 
Choroid plexus expression of APP(SwInd) impairs behavior  
Because altering APP expression selectively in the ChPl impacted neurogenic niches, we 
hypothesized that favoring the production of Aβ specifically in ChPl could negatively affect 
niche functions. To explore this possibility, we overexpressed a mutated form of human APP 
(Swedish K670N/M671L and Indiana V17F mutations) specifically in the ChPl of wild type 
mice at 3 months of age (Fig. 4a). The consequences of this gain-of-function were evaluated 3 
and 12 months after injection (when mice were 6 and 15 months old, respectively). We found 
strong hAPP(SwInd) mRNA expression in ChPl after 3 months which increased more than 3-
fold by 12 months (Fig. 4b). Strikingly, proliferation was significantly decreased at 3 months 
post-injection in both SVZ and DG of hAPP(SwInd) expressing mice. However, no difference 
was seen at 12 months post-injection (Fig. 4c-d), although this is likely due to the extremely 
low levels of proliferation also observed in control mice that may preclude further reduction. 
Indeed, proliferation already dramatically decreases from the time of injection at 3 months (‘No 
injection’ in Fig. 4c-d) to 6 months (3 months post-injection) in both niches, and further 
decreases in the DG at 15 months (12 months post-injection) as previously reported [9]. This 
decrease in proliferation was not due to amyloid plaque accumulation, as none was observed in 
the cortex or hippocampus of mice expressing the human APP(SwInd) in the ChPl (data not 
shown).  
We also evaluated spatial memory by using the Morris water maze reversal learning paradigm 
at either 3 months or 12 months post-injection (Fig. 4e). Mice from either group had not been 
subjected to previous spatial memory tests. During the learning phases, all groups showed 
significant improvement in latency to find the hidden platform after 5 days of training, but no 
differences were observed between groups (control and hAPP(SwInd)) in either latency or 
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swimming speed at both ages (Supp. Fig. 1). During probe tests, platforms were removed and 
performance was evaluated by the time spent in the target platform quadrant, the number of 
platform area crossings, and the mean total distance taken to reach the platform area (Fig. 4f-
h). At either 3 months or 12 months post-injection, hAPP(SwInd) mice showed no difference 
in performance compared to controls during probe test 1 (initial learning). Performance after 
probe test 2 (reversal learning) was unchanged in 6-month old mice (3 months post-injection) 
but showed significant differences for all parameters at 15 months (12 months post-injection). 
The time spent in the trained target quadrant was decreased, as was the number of platform area 
crossings, while the mean distance to find the platform area was increased, indicating that 
reversal learning is impaired after long-term ChPl expression of hAPP(SwInd).  
 
Choroid plexus expression of App(SwInd) impairs synaptic plasticity  
Compromised reversal learning may be rooted in plasticity-dependent deficits in hippocampal-
dependent spatial memory. Interestingly, mouse models of AD show a marked decrease in 
hippocampal CA1 synaptic plasticity in the form of long-term potentiation (LTP) at 4 months 
of age [20]. We thus assessed synaptic function at Schaffer collateral CA3 to CA1 synapses in 
the hippocampus of 15-month old mice expressing hAPP(SwInd) in the ChPl after receiving 
AAV5 icv injections at 3 months of age (Fig. 5a). We found no change in basal synaptic 
transmission in CA1 as shown by comparable input/output curves (F>1) (Fig. 5b). However, 
paired-pulse facilitation, a form of short-term plasticity reflecting presynaptic function, is 
increased in mice expressing mutated APP thus indicating a decrease in pre-synaptic release 
probability (Fig. 5c). Consistently, induction of LTP by high-frequency stimulation is 
significantly impaired in AAV5-hAPP(SwInd) injected mice (Fig. 5d), revealing impaired 
plasticity which corroborates observed deficits in spatial memory (Fig. 4f-h). 
 
 
Discussion 
The present study takes its origin in the growing interest for the ChPl, a structure increasingly 
recognized for its physiological importance beyond its classical “kidney of the brain” functions 
as it secretes CSF containing a plethora of trophic compounds [13]. Among these compounds 
are growth factors, guidance cues and morphogens, some of which gain access to the SVZ and 
participate in the regulation of neuroblast migration [11, 31, 39]. sAPPα infused into the CSF 
has been shown to increase proliferation and progenitor cell numbers in the SVZ [4, 8], with 
binding sites on type C and type A progenitor cells [4]. Given the very high expression of APP 
by the ChPl, we hypothesized that sAPPα could be secreted by the ChPl into the CSF and 
participate in adult neurogenesis. By conditionally knocking down App expression specifically 
in the ChPl through either genetic deletion or shRNA expression, we establish that ChPl APP 
has neurogenic activity not only in the SVZ but surprisingly also in the DG. Furthermore, this 
reduced proliferation can be reversed by the infusion of sAPPα into the CSF. Thus, sAPPα 
secreted by the ChPl can not only gain access to cells within the “superficial” SVZ, which 
contact lateral ventricles, but also to cells within the “deeper” DG within the parenchyma. Such 
transport has been reported for transcription factors secreted into the CSF by the ChPl [41]. 
Together, these results strongly suggest that sAPPα secreted by the ChPl functions as a 
neurogenic factor, further confirming ChPl as a major actor in regulating adult neurogenesis. 
The full range of functions of the APP family have yet to be fully identified, but several studies 
strongly suggest important developmental and physiological roles [28]. Some functions involve 
cis or trans dimer interactions between transmembrane APP molecules, and others involve 
heterodimers between transmembrane APP and secreted sAPPα [23]. These interactions 
modulate important processes including cell adhesion, synapse formation, synapse stabilization 
and cell survival [28]. Full-length transmembrane APP or sAPPα also interact with a large 
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number of other trans and cis interactors, thus acting as ligands or receptors in a variety of 
signaling pathways [28]. Some of these properties are attributed to the extracellular C-terminal 
16 amino acids of sAPPα, as compared to sAPPβ. For example, acute in vitro or in vivo 
application of sAPPα but not sAPPβ rescues hippocampal LTP in the adult brain of conditional 
double knockout mice lacking APP and the related protein APLP2 [17, 33]. This C-terminal 
sequence facilitates synaptic plasticity in the hippocampus through binding to functional 
nicotinic α7-nAChRs [26, 33]. In keeping with previous results [8], we also find that in vivo icv 
infusion of sAPPα, but not sAPPβ, positively impacts neurogenic niche cell proliferation in the 
adult mouse brain. While the reason for this functional divergence between sAPPα and sAPPβ 
for proliferation remains unknown, a shift in APP processing towards the amyloidogenic 
pathway would clearly impair both synaptic plasticity and neurogenesis.  
Mouse models developed to analyze the role of specific human APP mutations typically employ 
mutated genes often expressed throughout the brain and even the body. Our study is unique in 
that it explores whether expressing mutated APP only in the ChPl of adult mice (3 months old) 
could affect neurogenic niche proliferation and trigger learning defects. We found that ChPl 
expression of the human APP(SwInd) mutant, which favors sAPPβ and Aβ peptide formation, 
decreases proliferation at 3 months after infection (6 months old) with no change at 12 months 
after infection (15 months old), probably due to the fact that neurogenesis is naturally low at 15 
months and cannot be further reduced. However, a reversal learning test showed a significant 
decrease in the cognitive performance of these mice at 15 months. Accordingly, 
electrophysiological analysis at 15 months revealed decreased pre-synaptic release probability 
and impaired synaptic plasticity. No amyloid plaques were observed in these mice, leading us 
to speculate that the functional outcome of increased sAPPβ and Aβ accumulation is rooted in 
either synaptic deficits, reduced neurogenesis, and/or neuronal aging [42]. Given that sAPPβ 
icv infusion does not affect proliferation in the neurogenic niches, it is more likely that the 
observed deficits are due to increased Aβ (soluble or oligomers). Finally, while we observe no 
change in proliferation at 15 months, we cannot discount a negative long-term effect of ChPl 
human APP(SwInd) on the shaping of hippocampal synaptic circuits due to impaired 
proliferation during aging.  
Our findings strengthen the unique role played by the ChPl in regulating adult neurogenesis, 
and it is important to consider the morphological and transcriptomic alterations of the ChPl 
during normal aging and in late-onset AD that can impact brain homeostasis [35-37, 39]. These 
alterations can lead to changes in blood-CSF barrier properties, in ChPl function regulation, as 
well as in CSF composition and turnover. Furthermore, adult neurogenesis failure clearly plays 
a role in the development of AD in familial and possibly sporadic AD patients [14, 15, 25, 27, 
34, 45] and could be in part responsible for the decrease in neurogenesis observed in AD 
patients [25]. From a translational viewpoint, the fact that expressing a mutated APP gene 
exclusively in the ChPl can alter the cognitive abilities of mice raises the possibility that 
modifying the expression of APP or targeting APP mutations specifically in the ChPl, a 
structure accessible from the venous compartment [41], may represent a novel means to 
alleviate the burden associated with AD.  
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Figure Legends 
 
Figure 1. Choroid plexus App loss-of-function in Appflox/flox mice decreases adult neural 
progenitor proliferation. 
a Quantitative PCR analysis of App expression in ChPl from ventricles (LV and 4V), SVZ, and 
Hc. Values are normalized to GAPDH and expression in Hc (Veh n = 4, Cre-Tat n=7). 
b Schematic of App ChPl knock-down model involving single icv injection of Veh or Cre-Tat 
in adult Appflox/flox mice. 
c App specific recombination in LV choroid plexus after Cre-Tat icv injection. PCR of genomic 
DNA extracted from indicated structures. Grey arrow indicates App wild type locus, black 
arrow indicates deleted App locus upon Cre recombination.  
d Quantitative PCR analysis of App expression normalized to GAPDH after Cre-Tat or Veh icv 
injection (Veh n = 10, Cre-Tat n=10). 
e-f Western blot analysis (e) of various brain structures after Cre-Tat or Veh icv injection for 
quantification (f) of APP protein levels normalized to actin (Veh n = 10, Cre-Tat n=10). 
g Schematic of sAPPα rescue paradigm for evaluating SVZ cell proliferation. sAPPα was 
infused by 15-day osmotic mini-pump implanted immediately after Cre-Tat icv injection.  
h Analysis of SVZ cell proliferation by quantification of Ki67 positive cells after Veh or Cre-
Tat icv injection followed by infusion of Veh or sAPPα (Veh/Veh n=7, Cre-Tat/Veh n= 6, Cre-
Tat/sAPPα n=7). 
i Schematic of App ChPl knock-down with environmental enrichment (running wheel) for 
evaluating DG cell proliferation. 
j Analysis of DG cell proliferation by quantification of Ki67 positive cells after App 
recombination in mice in normal conditions or after physical exercise (Veh n=7, Cre-Tat n=8). 
*p<0.05; **p<0.01; t test in d, f, and j; one-way ANOVA in h; all values, mean ±SEM. LC, 
lateral ventricle; 4V, 4th ventricle; ChPl, choroid plexus; Hc, hippocampus; Cx, cortex; Ret, 
retina; SVZ, subventricular zone; DG, dentate gyrus; icv, intracerebroventricular; Veh, vehicle. 
 
Figure 2. Knock-down of choroid plexus App expression reduces cell proliferation in 
neurogenic niches. 
a Schematic of App ChPl knock-down model involving a single icv injection of AAV5 
expressing shRNA targeting the mouse Aβ42 sequence in wild type mice. Control virus 
expresses a scrambled Aβ42 shRNA devoid of targets in mouse. 
b An icv injection of AAV5 leads to specific choroid plexus expression. Note the absence of 
eGFP in brain parenchyma. Scale bar, 80 µm. 
c Quantitative PCR analysis of App expression in the ChPl, Hc, and Cx after ChPl App knock-
down (shRNA-mAβ42 n=4, shRNA-scrambled n=4). 
d-e Western blot analysis (d) of various brain structures after ChPl App knock-down for 
quantification (e) of APP protein levels normalized to actin (shRNA-mAβ42 n=4, shRNA-
scrambled n=4).  
f-i Analysis of cell proliferation in SVZ (f,g) and DG (h,i) by quantification of Ki67 positive 
cells after ChPl App knock-down (shRNA-mAβ42 n=7, shRNA-scrambled n=5). Arrows (f) 
highlight regional differences in SVZ cells. Scale bars, 100 µm. 
**p<0.01; ***p<0.001; t test; all values, mean ± SEM. ChPl, choroid plexus; Hc, hippocampus; 
Cx, cortex; SVZ, subventricular zone; DG, dentate gyrus; icv, intracerebroventricular.  
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Figure 3. sAPPα gain-of-function in the cerebral ventricles increases cell proliferation in 
neurogenic niches. 
a Schematic of sAPP icv infusion by 7-day osmotic mini-pump in adult wild type mice. 
b-c Analysis of cell proliferation in SVZ (b) and DG (c) by quantification of Ki67 positive cells 
after icv infusion of sAPPα or Veh (Veh n=9, sAPPα n=9). 
d-e Analysis of cell proliferation in SVZ (d) and DG (e) by quantification of Ki67 positive cells 
after icv infusion of sAPPβ or Veh (Veh n=5, sAPPβ n=5). 
f Schematic of App ChPl gain-of-function model involving a single icv injection of AAV5 
expressing mouse App or eGFP (control) in wild type mice. 
g Quantitative PCR analysis of App expression in ChPl after AAV5 icv injection (AAV5-mAPP 
n=4, AAV5-eGFP n=3). 
h-i Analysis of cell proliferation in SVZ (h) and DG (i) by quantification of Ki67 positive cells 
after icv injection (AAV5-mAPP n=6, AAV5-eGFP n=5).  
*p<0.05; **p<0.01; ***p<0.001; t test; all values, mean ± SEM. ChPl, choroid plexus; Hc, 
hippocampus; SVZ, subventricular zone; DG, dentate gyrus; icv, intracerebroventricular; Veh, 
vehicle.  
 
Figure 4. Choroid plexus hAPP(SwInd) expression decreases proliferation in neurogenic 
niches and impairs reversal learning. 
a Schematic of mutant APP ChPl model involving a single icv injection of AAV5 expressing 
human mutated APP or eGFP (control) in wild type mice. 
b Quantitative PCR analysis of ChPl viral expression of hAPP(SwInd) in WT mice at 3- and 
12-months post-injection (n=6 per group). 
c-d Quantification of Ki67 positive cells in SVZ (c) and DG (d) after ChPl viral expression 
(AAV5-eGFP n=6, AAV5-hAPP(SwInd) n=12). 
e Reversal learning paradigm. 
f-h Behavioral responses after probe test 1 (Initial) and probe test 2 (Reversal) quantified by 
time (f), activity (g) and distance (h) (6 months: AAV5-eGFP n=9, AAV5-hAPP(SwInd) n=11; 
15 months: AAV5-eGFP n=11, AAV5-hAPP(SwInd) n=10). 
*p<0.05; **p<0.01; ***p<0.001; t test; all values: mean ± SEM. SVZ, subventricular zone; 
DG, dentate gyrus; NE, not expressed; icv, intracerebroventricular.  
 
Figure 5. Choroid plexus hAPP(SwInd) expression impairs hippocampal LTP. 
a Schematic of mutant APP ChPl model involving a single icv injection of AAV5 expressing 
human mutated APP(SwInd) or eGFP (control) in wild type mice. 
b Comparaison of stimulus-response (input/output) relationship in CA1 region between AAV5-
hAPP(SwInd) (N=5, n=13, black squares) and AAV5-eGFP (N=7, n=10, red dots) injected 
mice. 
c Comparison of paired pulse facilitation between AAV5-hAPP(SwInd) (N=6, n=13) and 
AAV5-eGFP (N=8, n=13) injected mice. 
d LTP was induced by high frequency stimulation (HFS) at Schaffer collateral-CA1 synapses 
after 20 min baseline recording of slices from mice injected with AAV5-hAPP(SwInd) 
(N=4, n=9) or AAV5-eGFP (N=5, n=7). Representative traces showing responses before 
(dashed line) and 60 min after tetanus delivery (bold line). 
*p<0.05; ANOVA; all values: mean ± SEM; N, number of animals; n, number of slices; icv, 
intracerebroventricular. Calibration bars: 10 ms, 0.2 mV. 
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Fig. S1 Morris water maze escape latency and speed measured during acquisition phases.  
a-d At 3 months post viral injection, recordings performed during the 5 day initial learning 
phase (a,c) or reversal learning phase (b,d) to determine displacement speed (a,b) and mean 
escape latency (c,d). 
e-h At 12 months post viral injection, recordings performed during the 5 day initial learning 
phase (e,g) or reversal learning phase (f,h) to determine displacement speed (e,f) and mean 
escape latency (g,h). Two-way repeated measures ANOVA; all values ±SEM. 
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